Document is current
Any future updates will be listed below
-
Authors
Vogel, Marco M. E.
Rauscher, Isabel
Gschwend, Jürgen E.
Hekimsoy, Türkay
Gabler, Nicola
Olufs, Charlotte
D’Alessandria, Calogero
Peeken, Jan C.
Combs, Stephanie E.
Eiber, Matthias
-
Funding
Funding for this research was provided by:
Technische Universität München
- License Information
-
More Information
Article History
Received: 1 May 2024
Accepted: 11 December 2024
First Online: 17 January 2025
Declarations
:
: Matthias Eiber reports fees from Blue Earth Diagnostics Ltd. (consultant, research funding), Novartis/AAA (consultant, speaker), Telix (consultant), Bayer (consultant, research funding), RayzeBio (consultant), Point Biopharma (consultant), Eckert-Ziegler (speaker) and Janssen Pharmaceuticals (consultant, speakers bureau), Parexel (image review) and Bioclinica (image review) outside the submitted work and a patent application for rhPSMA. He and other inventors are entitled to royalties on sales of POSLUMA®. Isabel Rauscher reports research funding and travel support from Blue Earth Diagnostics. All other authors have no conflicts of interest to declare that are relevant to the content of this article.
